ProCE Banner Activity

Switching to Long-Acting Cabotegravir Plus Rilpirivine for HIV Treatment: Assessing Candidacy and Patient Counseling

Podcast Episodes
This podcast episode features an international panel discussion on the nuts and bolts of switching patients to long-acting injectable cabotegravir plus rilpivirine for HIV treatment.

Released: July 14, 2022

Expiration: July 13, 2023

Share

Faculty

Yvonne Gilleece

Yvonne Gilleece, MB BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Cristina Mussini

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Babafemi Taiwo

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Darrell H S Tan

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Provided by

Provided by Clinical Care Options, LLC.
ProCE Banner

Supporters

Supported by an educational grant from

ViiV Healthcare

Faculty Disclosure

Primary Author

Yvonne Gilleece, MB BCh, BAO, FRCP

Honorary Clinical Professor and Consultant in HIV Medicine & Sexual Health
Brighton & Sussex Medical School and University Hospitals Sussex NHS Foundation Trust
Chair of the British HIV Association
Lead for HIV & Women
Lead for HIV & Hepatitis
Brighton, United Kingdom

Yvonne Gilleece, MB, BCh, BAO, has disclosed that she has received payment for educational meetings from ViiV, advisory board fees from Gilead Sciences and ViiV, and conference sponsorship from Gilead Sciences.

Cristina Mussini, MD

Director of Infectious Diseases Clinics
Professor of Infectious Diseases
University of Modena School of Medicine
Modena, Italy

Cristina Mussini, MD, has disclosed that she has received consulting _x000b_fees from AbbVie, Angelini, Gilead Sciences, Janssen, MSD, and ViiV Healthcare and funds for research support from Gilead Sciences, Janssen, MSD, and ViiV Healthcare.

Babafemi Taiwo, MBBS

Assistant Professor
Division of Infectious Diseases
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Babafemi Taiwo, MBBS, has disclosed that he has received consultant/advisor/speaker fees from Gilead Sciences, Merck, and ViiV Healthcare/GSK and funds for independent contractor from Johnson & Johnson.

Darrell H S Tan, MD, FRCPC, PhD

Clinician-Scientist
Division of Infectious Diseases
St Michael's Hospital
Toronto, Ontario, Canada

Darrell H. S. Tan, MD, FRCPC, PhD, has disclosed that he has received funds for research support from AbbVie, Gilead Sciences, and GlaxoSmithKline.